GENORAY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,260 KRW | -0.63% |
|
-1.57% | -10.57% |
| 04-19 | Genoray Co., Ltd. announces an Equity Buyback for KRW 4,000 million worth of its shares. | CI |
| 04-19 | Genoray Co., Ltd. authorizes a Buyback Plan. | CI |
| Sales 2022 | 82.6B 59.81M 4.78B | Sales 2023 | 97.9B 70.88M 5.66B | Capitalization | 95.6B 69.21M 5.53B |
|---|---|---|---|---|---|
| Net income 2022 | 13.9B 10.06M 804M | Net income 2023 | 12.49B 9.04M 723M | EV / Sales 2022 | 1.13 x |
| Net cash position 2022 | 14.58B 10.56M 844M | Net Debt 2023 | 4.94B 3.58M 286M | EV / Sales 2023 | 1.03 x |
| P/E ratio 2022 |
7.83
x | P/E ratio 2023 |
7.68
x | Employees | 268 |
| Yield 2022 |
2.07% | Yield 2023 |
2.29% | Free-Float | 64.74% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.63% | ||
| 1 week | -1.57% | ||
| Current month | -7.81% | ||
| 1 month | -7.67% | ||
| 3 months | -9.28% | ||
| 6 months | -6.85% | ||
| Current year | -10.57% |
1 week
6 170.00
6 410.00
1 month
5 880.006 860.00
Current year
5 880.007 160.00
1 year
5 880.008 590.00
3 years
5 880.0011 800.00
5 years
4 510.0013 150.00
10 years
4 510.0015 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Byung-Uk Park
CEO | Chief Executive Officer | 62 | - |
Chan-Soo Kim
DFI | Director of Finance/CFO | 59 | - |
Bong-Gu Lee
CTO | Chief Tech/Sci/R&D Officer | 59 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bong-Gu Lee
CTO | Chief Tech/Sci/R&D Officer | 59 | - |
Byung-Uk Park
CEO | Chief Executive Officer | 62 | - |
Chan-Soo Kim
DFI | Director of Finance/CFO | 59 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 6,260 | -0.63% | 46,336 |
| 25/04/24 | 6,300 | 0.00% | 75,813 |
| 24/04/24 | 6,300 | +0.64% | 86,746 |
| 23/04/24 | 6,260 | -0.16% | 25,005 |
| 22/04/24 | 6,270 | -1.42% | 53,108 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
GENORAY CO., LTD is a Korea-based company that manufactures and sells hospital and dental X-ray imaging diagnostic equipments. The Company operates its business through two segments. The Medical segment manufactures and sells mobile C-arm and mammography equipments. The Dental segment manufactures and sells panoramic equipment, cephalometry equipment, 3D computed tomography (CT), portable X-ray equipment.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.57% | 62.11M | |
| -5.77% | 14.68B | |
| -40.71% | 2.71B | |
| -12.92% | 2.44B | |
| -8.78% | 1.51B | |
| -.--% | 1.12B | |
| +40.66% | 518M | |
| +11.68% | 239M | |
| +1.67% | 183M | |
| -.--% | 168M |
- Stock Market
- Equities
- A122310 Stock
